Prospective Grant of Exclusive Patent License: Development of a NANOG-Based Therapeutic for Cancer, 69544-69545 [2016-24133]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES 69544 Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices Contact Person: Jian Cao, MD. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Vascular Biology and Pathobiology. Date: November 3–4, 2016. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817, (Virtual Meeting). Contact Person: Ai-Ping Zou, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD 20892, 301–408– 9497, zouai@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Bioengineering Sciences #3. Date: November 3, 2016. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Joseph Thomas Peterson, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD 20892, 301–408– 9694, petersonjt@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Cell and Tissue Engineering and Analysis using Microfluidics, Bioprinting, and Bioreactors. Date: November 4, 2016. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Capital View, 2850 South Potomac Avenue, Arlington, VA 22202. Contact Person: Wenchi Liang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3150, MSC 7770, Bethesda, MD 20892, 301–435– 0681, liangw3@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR: Development of Pediatric Formulations and Drug Delivery Systems. Date: November 4, 2016. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Sharon S Low, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 5104, Bethesda, MD 20892–5104, 301– 237–1487, lowss@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846– 93.878, 93.892, 93.893, National Institutes of Health, HHS). VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 Dated: September 29, 2016. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24124 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive Patent License: Development of a NANOGBased Therapeutic for Cancer National Institutes of Health. Notice. AGENCY: ACTION: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Summary Information section of this notice to Inova Health System located in Falls Church, VA. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before October 21, 2016 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Kevin W. Chang, Ph.D., Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702 Telephone: (240) 276–6910; Facsimile: (240) 276–5504 Email: changke@mail.nih.gov. SUPPLEMENTARY INFORMATION: SUMMARY: Intellectual Property United States Provisional Patent Application No. No. 61/420,214, filed December 6, 2010, entitled ‘‘Allele Specific shRNAs For NANOG, Pharmaceutical Composition Comprising The shRNA, And Its Method of Use to Treat Cancer’’ [HHS Reference No. E–294–2010/0–US–01]; International PCT Application No. PCT/ US2011/063451, filed December 6, 2011, entitled ‘‘Pharmaceutical Composition Comprising NANOG shRNA, and Method of Using NANOG shRNA to Treat Cancer’’ [HHS Reference No. E–294–2010/0–PCT–02]; United States Patent No. 9,163,236, issued October 20, 2015, entitled PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 ‘‘Pharmaceutical Composition Comprising NANOG shRNA, and Method of Using NANOG shRNA to Treat Cancer’’ [HHS Ref. No. E–294– 2010/0–US–03]; and United States Patent Application No. 14/886,970 filed October 19, 2015, entitled, ‘‘Pharmaceutical Composition Comprising NANOG shRNA, and Method of Using NANOG shRNA to Treat Cancer’’ [HHS Ref. No. E–294– 2010/0–US–04]. The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for the following: ‘‘Treatment or prevention of colorectal cancer in humans.’’ The subject technologies are short hair-pin RNAs which inhibit NANOG or NANOGP8 for the treatment of cancer and viral vectors that encode the RNAs. The first generation of these vectors were non-replicating lentiviral based vectors that were introduced into cancer cells as a standard form of RNA inhibition, blocking the expression of NANOG or NANOGP8 protein. The most current version of the subject technology utilizes conditionally replicating, oncolytic adenovirus vectors. These adenovirus-based vectors grow in cells that express NANOGP8 but not in cells that lack NANOGP8 or where the shRNA has inhibited NANOGP8 expression. The vectors have been constructed to directly kill tumors and to inhibit the NANOGs to block cancer stem cell function in the tumors. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Patent License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. E:\FR\FM\06OCN1.SGM 06OCN1 Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices Dated: September 29, 2016. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. DEPARTMENT OF THE INTERIOR [FR Doc. 2016–24133 Filed 10–5–16; 8:45 am] [178A2100DD/AAKC001030/ A0A501010.999900 253G] Bureau of Indian Affairs BILLING CODE 4140–01–P Renewal of Agency Information Collection for Grazing Permits Geological Survey Bureau of Indian Affairs, Interior. ACTION: Notice of submission to OMB. [GX17GG00995TR00] SUMMARY: AGENCY: DEPARTMENT OF THE INTERIOR Announcement of Scientific Earthquake Studies Advisory Committee Meeting U.S. Geological Survey, Department of the Interior. AGENCY: ACTION: Notice of meeting. The Scientific Earthquake Studies Advisory Committee (SESAC) will hold its next meeting in the Mesa Room of the Golden Hotel at 800 11th Street, Golden, Colorado. The Committee is comprised of members from academia, industry, and State government. The Committee shall advise the Director of the U.S. Geological Survey (USGS) on matters relating to the USGS’s participation in the National Earthquake Hazards Reduction Program. The Committee will receive reports on the status of activities of the Program and progress toward Program goals and objectives. The Committee will assess this information and provide guidance on the future undertakings and direction of the Earthquake Hazards Program. Focus topics for this meeting include a program review and strategic planning for 2016–2018. SUMMARY: The meeting will be held from 9:00 a.m. to 5:00 p.m. on November 7– 8, 2016. DATES: Dr. William Leith, U.S. Geological Survey, MS 905, 12201 Sunrise Valley Drive, Reston, Virginia 20192, (703) 648–6786, wleith@usgs.gov. FOR FURTHER INFORMATION CONTACT: Meetings of the Scientific Earthquake Studies Advisory Committee are open to the public. sradovich on DSK3GMQ082PROD with NOTICES SUPPLEMENTARY INFORMATION: Authority: Public Law 106–503. William Leith, Senior Science Advisor for Earthquake and Geologic Hazards. [FR Doc. 2016–24226 Filed 10–5–16; 8:45 am] BILLING CODE 4338–11–P VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 In compliance with the Paperwork Reduction Act of 1995, the Bureau of Indian Affairs (BIA) has submitted to the Office of Management and Budget (OMB) a request for renewal of the collection of information for Grazing Permits authorized by OMB Control Number 1076–0157. This information collection expires October 31, 2016. DATES: Interested persons are invited to submit comments on or before November 7, 2016. ADDRESSES: Please submit your comments to the Desk Officer for the Department of the Interior at the Office of Management and Budget, by facsimile to (202) 395–5806 or you may send an email to: OIRA_Submission@ omb.eop.gov. Also please send a copy of your comments to David Edington, Office of Trust Services, 1849 C Street NW., Mail Stop 4637 MIB, Washington, DC 20240; facsimile: (202) 219–0006; email: David.Edington@bia.gov. FOR FURTHER INFORMATION CONTACT: David Edington, Office of Trust Services, 1849 C Street NW., Mail Stop 4637 MIB, Washington, DC 20240; facsimile: (202) 219–0006; email: David.Edington@bia.gov. You may review the information collection request online at https:// www.reginfo.gov. Follow the instructions to review Department of the Interior collections under review by OMB. SUPPLEMENTARY INFORMATION: I. Abstract The ‘‘American Indian Agricultural Resource Management Act,’’ (AIARMA), 25 U.S.C. 3701 et seq., authorizes the Secretary of the Interior, in participation with the beneficial owner of the land, to manage Indian agricultural lands in a manner consistent with identified Tribal goals and priorities for conservation, multiple use, sustained yield, and consistent with trust responsibilities, related to grazing on Tribal land, individually-owned Indian land, or government land. The regulations at 25 CFR 166, Grazing Permits, implement PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 69545 the AIARMA and include the specific information collection requirements. This information collection allows BIA to obtain the information necessary to determine whether an applicant is eligible to acquire, modify, or assign a grazing permit on trust or restricted lands and to allow a successful applicant to meet bonding requirements. Some of this information is collected on forms. The burden hours for this continued collection of information are reflected in the Estimated Total Annual Hour Burden in this notice. II. Request for Comments The BIA requests your comments on this collection concerning: (a) The necessity of this information collection for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) The accuracy of the agency’s estimate of the burden (hours and cost) of the collection of information, including the validity of the methodology and assumptions used; (c) Ways we could enhance the quality, utility, and clarity of the information to be collected; and (d) Ways we could minimize the burden of the collection of the information on the respondents. Please note that an agency may not conduct or sponsor and an individual need not respond to, a collection of information unless it displays a valid OMB Control Number. It is our policy to make all comments available to the public for review at the location listed in the ADDRESSES section. Before including your address, phone number, email address or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. III. Data OMB Control Number: 1076–0157. Title: Grazing Permits, 25 CFR 166. Brief Description of Collection: Submission of this information allows individuals or organizations to acquire or modify a grazing permit on Tribal land, individually-owned Indian land, or government land and to meet bonding requirements. Some of this information is collected on the following forms: Form 5–5423— Performance Bond, Form 5–5514—Bid for Grazing Privileges, 5–5515 Grazing Permit, Form 5–5516—Grazing Permit for Organized Tribes, Form 5–5517— E:\FR\FM\06OCN1.SGM 06OCN1

Agencies

[Federal Register Volume 81, Number 194 (Thursday, October 6, 2016)]
[Notices]
[Pages 69544-69545]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24133]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Development of a 
NANOG-Based Therapeutic for Cancer

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive patent license to practice the 
inventions embodied in the U.S. Patents and Patent Applications listed 
in the Summary Information section of this notice to Inova Health 
System located in Falls Church, VA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before October 21, 2016 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Kevin W. Chang, Ph.D., Senior Licensing and Patenting 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702 Telephone: (240) 276-6910; Facsimile: (240) 276-5504 
Email: changke@mail.nih.gov.

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    United States Provisional Patent Application No. No. 61/420,214, 
filed December 6, 2010, entitled ``Allele Specific shRNAs For NANOG, 
Pharmaceutical Composition Comprising The shRNA, And Its Method of Use 
to Treat Cancer'' [HHS Reference No. E-294-2010/0-US-01]; International 
PCT Application No. PCT/US2011/063451, filed December 6, 2011, entitled 
``Pharmaceutical Composition Comprising NANOG shRNA, and Method of 
Using NANOG shRNA to Treat Cancer'' [HHS Reference No. E-294-2010/0-
PCT-02]; United States Patent No. 9,163,236, issued October 20, 2015, 
entitled ``Pharmaceutical Composition Comprising NANOG shRNA, and 
Method of Using NANOG shRNA to Treat Cancer'' [HHS Ref. No. E-294-2010/
0-US-03]; and United States Patent Application No. 14/886,970 filed 
October 19, 2015, entitled, ``Pharmaceutical Composition Comprising 
NANOG shRNA, and Method of Using NANOG shRNA to Treat Cancer'' [HHS 
Ref. No. E-294-2010/0-US-04].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: ``Treatment or prevention of colorectal cancer in 
humans.''
    The subject technologies are short hair-pin RNAs which inhibit 
NANOG or NANOGP8 for the treatment of cancer and viral vectors that 
encode the RNAs. The first generation of these vectors were non-
replicating lentiviral based vectors that were introduced into cancer 
cells as a standard form of RNA inhibition, blocking the expression of 
NANOG or NANOGP8 protein. The most current version of the subject 
technology utilizes conditionally replicating, oncolytic adenovirus 
vectors. These adenovirus-based vectors grow in cells that express 
NANOGP8 but not in cells that lack NANOGP8 or where the shRNA has 
inhibited NANOGP8 expression. The vectors have been constructed to 
directly kill tumors and to inhibit the NANOGs to block cancer stem 
cell function in the tumors.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Exclusive Patent License Agreement. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.


[[Page 69545]]


    Dated: September 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2016-24133 Filed 10-5-16; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.